Shares of Pharmaceutical company Cytokinetics climbed 6.4% this afternoon. Here are some quick facts to get you started if you are interested in the stock:
-
Cytokinetics has logged a 2.7% 52 week change, compared to 17.9% for the S&P 500
-
CYTK has an average analyst rating of buy and is -19.75% away from its mean target price of $75.5 per share
-
Its trailing earnings per share (EPS) is $-5.12, which brings its trailing Price to Earnings (P/E) ratio to -11.8. The Health Care sector's average P/E ratio is 22.94
-
The company's forward earnings per share (EPS) is $-5.39 and its forward P/E ratio is -11.2
-
The current ratio is currently 6.2, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-399796000 and the average free cash flow growth rate is -52.9%
-
Cytokinetics's revenues have an average growth rate of -14.9% with operating expenses growing at 32.1%. The company's current operating margins stand at -2902.7%